Shares of Crescent Biopharma Inc. (CBIO), an oncology company, began trading on the Nasdaq Capital Market on June 16, 2025, following a reverse merger with GlycoMimetics Inc. (Nasdaq: GLYC).
Crescent's investigational cancer programs feature a dual-action antibody as a core treatment, plus antibody-drug conjugates that can work alone or alongside its investigational immunotherapy. The lead drug candidate is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.